TRMT13

Across TCGA pan-cancer cohorts, TRMT13 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRMT13 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TRMT13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT13 expression acts as an unfavorable survival marker, although some lineages such as KIRC show a favorable association.

BRCA, CHOL, and KIRC are the cancer types where TRMT13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.165	0.833	<.001	28	view →
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
KIRC	DFS	Median	IV	1.000	0.229	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRMT13–BRCA (OS)

Open the BRCA breakdown →